ABP 234 (pembrolizumab biosimilar candidate)

ABP 234 is Amgen's proposed biosimilar of pembrolizumab - Merck's Keytruda, the best-selling cancer drug in the world. Amgen is running two Phase 3 studies: a pharmacokinetic similarity trial (NCT06430866, n=163) and a comparative efficacy and safety study in non-squamous non-small cell lung cancer (NCT06311721, n=315). Both are listed as active, not recruiting on ClinicalTrials.gov [1][2]. This matters because Keytruda generated roughly $29.5 billion in 2024 revenue for Merck, the largest single-product revenue line in pharma, and its main US composition-of-matter patent expires in June 2028 [3][7]. Whoever has a biosimilar approved and ready to ship at launch captures the first wave of market share. Amgen brings manufacturing capacity and a commercial team that already sells biosimilars of bevacizumab (Mvasi), trastuzumab (Kanjinti), adalimumab (Amjevita), and infliximab (Avsola) [4]. That makes them one of several credible candidates in the pembrolizumab biosimilar race, alongside Celltrion (CT-P51), Bio-Thera (BAT3306), Alvotech/Dr. Reddy's, Sandoz (GME751), and Samsung Bioepis [9][10][11].

ABP 234 is not a novel compound. It's a proposed biosimilar copy of pembrolizumab. The regulatory pathway is the 351(k) BLA under the Biologics Price Competition and Innovation Act, which lets sponsors skip large efficacy studies if they show structural and functional similarity to the reference product, plus PK and clinical equivalence [5]. Biosimilars don't get breakthrough therapy or orphan designations - those are reserved for novel drugs addressing unmet need. A separate FDA determination, interchangeability, allows pharmacist-level substitution without prescriber involvement and requires additional switching study data; whether Amgen is pursuing interchangeability for ABP 234 has not been publicly disclosed and is a material commercial question, since interchangeability designations drove rapid uptake of adalimumab biosimilars [5]. Both Phase 3 trials are listed as active, not recruiting, meaning enrollment is closed and follow-up is ongoing [1][2]. Amgen has not publicly disclosed top-line data timing or BLA submission timing for ABP 234. The commercial timing constraint is Keytruda's IP cliff: the US composition-of-matter patent expires June 2028, with Merck likely defending fringe patents and pivoting volume to a subcutaneous pembrolizumab formulation (Keytruda Qlex, FDA-approved September 19, 2025) that may shift the addressable market away from IV biosimilars in many indications [7][8]. Realistic biosimilar US launch is 2028 or later, with EU launches plausible in a similar window. Amgen has already commercialized at least four biosimilars through FDA, which puts them in the top tier of biosimilar developers globally [4].

Pembrolizumab is a monoclonal antibody that blocks PD-1, a receptor on T cells that acts as an off switch. Tumors exploit this switch - they display PD-L1 on their surface, which engages PD-1 and tells the T cell to stand down. Blocking PD-1 keeps T cells active and lets the immune system attack the tumor. The mechanism is the most validated in modern oncology: pembrolizumab alone is approved across more than 30 indications, from melanoma to NSCLC to MSI-high colorectal cancer. The biology is settled. The PD-1/PD-L1 axis is the most heavily validated checkpoint in oncology - more than a dozen approved checkpoint inhibitors, including at least four that directly block PD-1 (pembrolizumab, nivolumab, cemiplimab, dostarlimab) and three that block its ligand PD-L1 (atezolizumab, durvalumab, avelumab). The target is maximally validated; novelty risk is zero. The question for a biosimilar is whether ABP 234 is sufficiently identical to Keytruda in structure, glycosylation (the sugar groups attached to the antibody, which affect how it binds receptors and how long it stays in circulation), and clinical effect to be considered biosimilar - and separately, interchangeable. Biosimilars are not generics. Antibodies are produced in living cells, and small differences in cell line, fermentation conditions, and purification can shift binding affinity, immunogenicity, and effector function. The regulatory bar is that ABP 234 must show no clinically meaningful difference from Keytruda in PK, efficacy, safety, and immunogenicity - not that it's atom-for-atom identical.

Two Phase 3 studies, both sponsored by Amgen, both listed as active and not recruiting [1][2]. NCT06430866 is the PK similarity study with 163 participants. The primary endpoint is area under the serum concentration-time curve from day 0 to day 21 after the first dose. PK studies for biosimilars are typically run in healthy volunteers or stable patients, and the bar is a 90% confidence interval on the geometric mean ratio falling within 80%-125% of the reference product. NCT06311721 is the comparative clinical study, 315 patients with advanced or metastatic non-squamous NSCLC, primary endpoint objective response rate. Patients receive either ABP 234 or Keytruda combined with platinum-based chemotherapy, mirroring the KEYNOTE-189 regimen that established pembrolizumab + pemetrexed + platinum as standard first-line therapy for non-squamous NSCLC [6]. Non-squamous NSCLC is a sensitive population for detecting differences because response rates are moderate and well-characterized. Both trials began in 2024 and are now in follow-up; for an ORR-anchored equivalence study in first-line NSCLC, primary readout is typically estimable 12-18 months after enrollment close, putting the most likely top-line window in late 2025 through 2026. This is an analyst estimate, not company guidance; Amgen has not disclosed readout timing. The design is conventional for an oncology biosimilar - equivalence margin on ORR plus immunogenicity and safety bridging. No obvious red flags. The risk is statistical rather than mechanistic: if the equivalence interval is too tight or the response rates drift, the trial can fail without anything being wrong with the drug.

Our model gives this drug a 51% chance of eventually being approved. That figure starts from the historical approval rate for Phase 3 drugs in this area - about 85% - then adjusts based on ten specific facts about the trial and sponsor. The estimate is nudged up by an unusually high number of secondary endpoints, and pulled down by the sponsor's thin approval record, weak earlier-phase results, and a randomized trial design. The remaining factors land close to average for this stage, so they don't shift the number much in either direction.

Biosimilar risks are not novel drug risks. Efficacy risk is narrow: the equivalence interval on ORR fails because response rates in either arm drift outside expected bounds, even though the drugs are biologically similar. Safety risk is mostly immunogenicity - different glycosylation or impurity profiles can trigger anti-drug antibodies that Keytruda doesn't, which neutralizes activity and creates infusion reactions. Manufacturing risk is real for biologics: Amgen has to demonstrate consistent product quality across batches, and inspection findings can delay BLA approval by quarters [4]. Commercial risk is the dominant concern. Merck has been aggressive about defending Keytruda revenue. Subcutaneous pembrolizumab (Keytruda Qlex) was FDA-approved on September 19, 2025 across the previously approved IV solid-tumor indications [8]; Merck's lifecycle strategy is to convert IV patients to subQ before biosimilars launch, which would shrink the addressable IV market for ABP 234. Patent litigation is likely; Merck has filed continuations on dosing regimens and combinations [3][7]. Payers may not aggressively prefer biosimilars over Keytruda the way they did for adalimumab biosimilars, because oncology biosimilar substitution moves slower and is rarely interchangeable at the pharmacy level - and Amgen has not publicly committed to seeking interchangeability for ABP 234. Competition is dense and differentiated by strategy: Celltrion (CT-P51) initiated a Phase 3 NSCLC equivalence trial in January 2025 and is on a similar timeline to Amgen [9]; Sandoz (GME751) and Bio-Thera (BAT3306) modified or skipped Phase 3 in favor of analytics-plus-Phase 1 BLA packages, which could compress their timeline if FDA accepts the strategy [10]; Alvotech/Dr. Reddy's announced their pembrolizumab biosimilar collaboration in June 2025 and are behind Amgen on clinical development [11]; Samsung Bioepis is also active. Amgen sits in the lead-pack on clinical execution but is not unambiguously first; first-to-launch matters more than fifth-to-launch.

Worth watching, but not for the science - this is a pure commercial play. The mechanism is settled, the molecule is a copy, the clinical trials are equivalence studies. The signal to look for is BLA submission timing relative to the June 2028 Keytruda US patent cliff [7]. Amgen's biosimilar track record (Mvasi, Kanjinti, Amjevita, Avsola) makes them a top-tier player in the pembrolizumab biosimilar race; on clinical execution they appear to be in the lead pack alongside Celltrion, with Sandoz and Bio-Thera potentially leapfrogging via analytics-based BLA packages and Alvotech/Dr. Reddy's behind [9][10][11]. The number that matters most is Merck's subcutaneous Keytruda conversion rate - Keytruda Qlex was approved September 2025, and if Merck successfully moves a majority of IV patients to subQ before biosimilars hit, the IV biosimilar market shrinks substantially [8]. Pricing math: oncology biosimilars typically launch at 15-35% discounts to the reference product. At a 25% discount to Keytruda's IV list price and Keytruda's roughly $29.5B 2024 revenue base, even a 5% market share capture across remaining IV indications represents a $1B+ revenue opportunity gross-to-net - material for any single biosimilar developer though smaller as a share of Amgen's $36.75B total revenue. Check back when (1) Amgen reports PK and efficacy readouts (estimable late 2025-2026), (2) Amgen announces BLA filing and whether interchangeability is sought, and (3) Merck reports subQ pembrolizumab uptake on quarterly earnings. For Amgen, ABP 234 is one of several pipeline biosimilars expected to contribute to the post-2028 biosimilar wave; it's not a needle-mover for a $36.75 billion-revenue company unless they capture meaningful first-wave share.